Yangchan Hu

Yangchan Hu

Auto-generated profile, based on publicly available information

Yangchan Hu


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
HCHongjie Chen
Hongjie Chen
YHYangchan Hu
Yangchan Hu
ZZZirui Zhuang
Zirui Zhuang
DWDingyi Wang
Dingyi Wang
ZYZu Ye
Zu Ye
XCXiangdong Cheng
Xiangdong Cheng
Gastric cancer (GC) is a common and aggressive cancer of the digestive system, exhibiting high aggressiveness and significant heterogeneity. Despite advancements in improving survival rates over the past few decades, GC continues to carry a worrisome prognosis and notable mortality. As a result, there is an urgent need for novel therapeutic approaches to address GC. Recent targeted sequencing studies have revealed frequent mutations in DNA damage repair (DDR) pathway genes in many GC patients. These mutations lead to an increased reliance on poly (adenosine diphosphate-ribose) polymerase (PARP) for DNA repair, making PARP inhibitors (PARPi) a promising treatment option for GC. This article presents a comprehensive overview of the rationale and development of PARPi, highlighting its progress and challenges in both preclinical and clinical research for treating GC.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Supplementary Tables S1, S2 and S3 list the plasmids, sgRNA/siRNA sequences, and qPCR primers used in this study, respectively.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S1 shows PARG upregulation, independent prognostic value, and PARG inhibitor characterization in GC.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S2 demonstrates that PARG inhibition synergizes with fluoropyrimidines.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S8 shows RAD51AP1 overexpression restores chemoresistance in PARG-deficient xenografts without toxicity.

15 September 2026
Verified
Other
Open access
HHHanyi He
Hanyi He
YHYangchan Hu
Yangchan Hu
YLYe Lu
Ye Lu
MDMingcong Deng
Mingcong Deng
QBQimei Bao
Qimei Bao
XCXiangdong Cheng
Xiangdong Cheng
Fig. S7 provides biochemical evidence of direct PARG–RAD51AP1 interaction and PAR-dependent ubiquitination.